why wouldn't they go with Histogen then, since Histogen's results seem stronger than Replicel's? I think Replicel must have upped the game in some form to get a legitimate investor when we have Gail from Histogen admitting that they can't afford a multi-country release and BTT members actually trying to create a kick starter for Histogen...
To me this suggests Replicel is more promising
To me this suggests Replicel is more promising
Comment